Thermo Fisher, Janssen to co-develop cancer CDx
May 2020—Thermo Fisher Scientific has signed an agreement with Janssen Biotech to co-develop a companion diagnostic in oncology. The diagnostic will support clinical trial enrollment worldwide.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Horizon CHOsource platform
May 2020—Horizon Discovery Group announced its cGMP-compliant CHOsource platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases. Horizon’s Chinese hamster ovary cells delivered high yields of monoclonal antibody for LAG-3 immunotherapy, the company reported in a press statement, enabling Immutep and Batavia Biosciences to reach a milestone in the preclinical development of the compound.
New books: pathology art, atlas, endocrine guide
April 2020—Sylvia L. Asa, MD, PhD, consultant in endocrine pathology, University Hospitals Cleveland Medical Center and University Health Network Toronto, and professor of pathology, Case Western Reserve University, served as an editor of two recently published books related to pathology and is a coauthor of the first book in series five of the AFIP Atlas of Tumor and Non-Tumor Pathology series. Dr. Asa showcased these books at this year’s USCAP meeting in Los Angeles. Art Gallery of Pathology (ARP Press), created by Tim-Rasmus Kiehl, MD, and edited by Dr. Asa, explores the use of human pathology samples as they are used to create art. Dr. Kiehl worked as a neuropathologist at University Health Network in Toronto.
Randox STI assay gets CE mark
April 2020—Randox announced that its Randox STI assay has received the CE mark. The multiplex assay detects 10 STIs, including co-infections, from a single patient sample. It tests simultaneously for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, Treponema pallidum, HSV-1, HSV-2, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum.
BD, Babson to enable blood collection in retail settings
April 2020—Becton Dickinson and Babson Diagnostics, a diagnostic blood testing company, announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies. BD’s capillary specimen collection devices, in development, are designed to enable the collection of laboratory-quality specimens without the need to access a vein and are for use in health care settings without a trained phlebotomist, such as retail pharmacies, physician offices, urgent care centers, and skilled nursing facilities. Babson’s offerings include proprietary automated sample handling and analytical technologies, which are also in development.
Leica Biosystems digital pathology scanner
April 2020—Leica Biosystems launched the Aperio GT 450, its next-generation digital pathology scanner. The research-use-only Aperio GT 450 offers continuous rack loading with priority scanning and takes 32 seconds to scan a 15 mm × 15 mm tissue area on a pathology slide at 40× magnification with a throughput of 81 slides per hour. The system’s slide racks are compatible with other Leica Biosystems products.
FDA authorizes marketing of Fragile X syndrome dx
April 2020—The FDA authorized the marketing of AmplideX Fragile X Dx and Carrier Screen Kit (Asuragen). It is the first test, according to the FDA, to detect Fragile X syndrome, the most common known cause of inherited developmental delay and intellectual disability. Additionally, this test is intended for use in adults who may be carriers of genetic alterations in the FMR1 gene.
FDA approves neratinib for metastatic HER2+ breast cancer
April 2020—The FDA approved neratinib (Nerlynx, Puma Biotechnology) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting.
New England Tissue Issue joins ProPath
April 2020—ProPath announced that New England Tissue Issue, a dermatopathology practice in Fall River, Mass., has joined the ProPath family of companies. The partnership will allow 8 million patients from NETI’s catchment area in-network access to ProPath’s esoteric testing.
Thermo Fisher digital dispensers
April 2020—Thermo Fisher Scientific launched the Thermo Scientific Multidrop Pico 1 and Pico 8 Digital Dispensers, designed to enable assay miniaturization, boost productivity, and improve accuracy of results. The systems dispense reagent volumes between 11 pL and 200 µL in any well and are suitable for a broad array of low-volume applications, including quantitative polymerase chain reactions, dose response curves, drug screening assays, serial dilutions, genotyping reactions, and enzyme-linked immunosorbent assays.